Saisheng Pharmaceuticals and SF Pharmaceuticals Sign Strategic Cooperation Agreement

Saisheng Pharmaceutical Holdings Co.
, Ltd.
and SF Pharmaceuticals officially announced that they will start a strategic cooperation on April 22, 2021, and SF Pharmaceuticals has become a GTP supply chain service provider certified by Saisheng Pharmaceuticals
.

The two parties will give full play to their respective advantages - relying on Saisheng Pharmaceutical's professional and deep cultivation in the field of life and health and SF Pharmaceutical's successful practice in the integrated digital supply chain and innovative operation model, to work together to create a more efficient life and health enterprise to C-end patient users Provide professional, safe, and traceable end-to-end services to build a higher standard for China’s GTP supply chain in the field of life and health

The signing ceremony of the strategic cooperation agreement was held in Beijing
.

Mr.

At the signing ceremony, Mr.
Zhao Hong, President and CEO of Saisheng Pharmaceutical, and Ms.
Zhou Shun, General Manager of SF Pharmaceutical, successively discussed the overall plan for strategic cooperation between the two parties and the innovative Go-To-Patient ("GTP") business model of Saisheng Pharmaceutical And SF's medical service information visualization innovative business model was shared and exchanged
.

Saisheng Pharmaceutical's GTP platform expands the sales channels of prescription drugs from hospitals to Direct-To-Patient ("DTP") pharmacies, increasing the availability of prescription drugs to patients

Mr.
Li Zhenfu, Chairman of Saisheng Pharmaceutical, Chairman and CEO of Telford Capital, said at the signing ceremony: “As an international biopharmaceutical company with an integrated platform for product development and commercialization, Saisheng Pharmaceutical has been deeply involved in China for more than 20 years.
upload
Isa Pharma since its inception, has been the health of patients, and insist that 'strict compliance, high performance' culture, provided the original research of high-quality products that meet international standards for patients
.

whether it is the core of its own products Zadaxin (thymalfasin New original research drugs), or the other 8 products under development, all have a huge market and continued high volume prospects in the field of oncology and anti-infection

Mr.

Lu Jun, Chairman of SF Pharmaceuticals, said in a speech: "We are very honored to be certified by Saisheng Pharmaceuticals, and we are full of confidence in this strategic cooperation

Value first, mutual empowerment, and common improvement
.

Saisheng Pharmaceutical Co.